GSK Cough Drug Failure Disappoints, but Market was Cautious

Dow Jones

Yesterday

0538 GMT - News that a GSK experimental drug for chronic cough achieved negative results in late-stage studies is disappointing, but the market was cautious on the product's chances, Citi analysts say in a research note. Some saw in the drug, camlipixant, a potential candidate to help the U.K. drugmaker offset the patent expiration of its dolutegravir HIV medication, the analysts say. Still, Citi saw the drug as a high-risk asset and assigned it a 25% probability of success in its estimates, equivalent to just 1% of expected GSK revenue for 2035, they add. Similarly, consensus was cautious, with estimated 2035 sales of 750 million pounds for camlipixant accounting for 2% of group revenue, according to Citi. GSK shares closed 2% lower on Friday. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

July 20, 2026 01:38 ET (05:38 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2652426246"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2652426246\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2652426246?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-20 13:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2652426246","market":"nz","top_or_hot":-1,"title":"GSK Cough Drug Failure Disappoints, but Market was Cautious","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0538 GMT - News that a GSK experimental drug for chronic cough achieved negative results in late-stage studies is disappointing, but the market was cautious on the product's chances, Citi analysts say in a research note. Some saw in the drug, camlipixant, a potential candidate to help the U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. drugmaker offset the patent expiration of its dolutegravir HIV medication, the analysts say. Still, Citi saw the drug as a high-risk asset and assigned it a 25% probability of success in its estimates, equivalent to just 1% of expected GSK revenue for 2035, they add. Similarly, consensus was cautious, with estimated 2035 sales of 750 million pounds for camlipixant accounting for 2% of group revenue, according to Citi. GSK shares closed 2% lower on Friday. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 20, 2026 01:38 ET (05:38 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GSK Cough Drug Failure Disappoints, but Market was Cautious</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGSK Cough Drug Failure Disappoints, but Market was Cautious\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-20 13:38</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0538 GMT - News that a GSK experimental drug for chronic cough achieved negative results in late-stage studies is disappointing, but the market was cautious on the product's chances, Citi analysts say in a research note. Some saw in the drug, camlipixant, a potential candidate to help the U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. drugmaker offset the patent expiration of its dolutegravir HIV medication, the analysts say. Still, Citi saw the drug as a high-risk asset and assigned it a 25% probability of success in its estimates, equivalent to just 1% of expected GSK revenue for 2035, they add. Similarly, consensus was cautious, with estimated 2035 sales of 750 million pounds for camlipixant accounting for 2% of group revenue, according to Citi. GSK shares closed 2% lower on Friday. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 20, 2026 01:38 ET (05:38 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GSKH","symbol_name":"GSK plc ADRhedged","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2652426246","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2652426246","pubTimestamp":1784525880,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0538 GMT - News that a GSK experimental drug for chronic cough achieved negative results in late-stage studies is disappointing, but the market was cautious on the product's chances, Citi analysts say in a research note. Some saw in the drug, camlipixant, a potential candidate to help the U.K. drugmaker offset the patent expiration of its dolutegravir HIV medication, the analysts say. Still, Citi saw the drug as a high-risk asset and assigned it a 25% probability of success in its estimates, equivalent to just 1% of expected GSK revenue for 2035, they add. Similarly, consensus was cautious, with estimated 2035 sales of 750 million pounds for camlipixant accounting for 2% of group revenue, according to Citi. GSK shares closed 2% lower on Friday.  Dow Jones NewswiresJuly 20, 2026 01:38 ET Copyright  2026 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GSKH":"GSK plc ADRhedged","GSK.UK":"葛兰素史克","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4532":"文艺复兴科技持仓","LU1829250122.USD":"高盛欧洲核心股票组合Acc","GSK":"葛兰素史克","BK4007":"制药"},"translate_title":"葛兰素史克止咳药失败令人失望，但市场持谨慎态度","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSK":1.5,"GSKH":0.6,"GSK.UK":0.6},"content_text":"0538 GMT - News that a GSK experimental drug for chronic cough achieved negative results in late-stage studies is disappointing, but the market was cautious on the product's chances, Citi analysts say in a research note. Some saw in the drug, camlipixant, a potential candidate to help the U.K. drugmaker offset the patent expiration of its dolutegravir HIV medication, the analysts say. Still, Citi saw the drug as a high-risk asset and assigned it a 25% probability of success in its estimates, equivalent to just 1% of expected GSK revenue for 2035, they add. Similarly, consensus was cautious, with estimated 2035 sales of 750 million pounds for camlipixant accounting for 2% of group revenue, according to Citi. GSK shares closed 2% lower on Friday. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 20, 2026 01:38 ET (05:38 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}